6% at the lumbar spine after 24 months, while alendronate increased BMD by up to 1
Kendler DL, Roux C, Benhamou CL, et al
alendronate could reduce risk of fracture [OR (95% CI) 1
Treatment with denosumab (Prolia ®) was associated with greater reductions in fracture risk over time in postmenopausal women compared with oral alendronate, according to new data They identified 10 studies that compared denosumab with one of four bisphosphonates, most often alendronate (Fosamax) (n = 6)
35% for total hip), thus showing the noninferiority of Prolia ® compared with alendronate
6%), bronchitis (6
0001
In two key publications, (1) the phase 3 Determining Efficacy: Comparison of Initiating Denosumab versus Alendronate (DECIDE) trial, in which treatment-naïve patients were randomized to alendronate or denosumab; and (2) a separate pooled analysis of four other studies, in which patients previously on a bisphosphonate were
Romosozumab vs
Introduction We conducted a patient-level pooled analysis of four studies to estimate the efficacy and safety of transitioning to
3 percent after eight years
Within 3 years of follow-up, initiation of denosumab or alendronate was associated with cumulative incidences of 3